Major Shifts in Outpatient Cirrhosis Care Delivery Attributable to the COVID‐19 Pandemic: A National Cohort Study

The coronavirus disease 2019 (COVID‐19) pandemic has disrupted health care delivery in the United States, with increased reliance on telemedicine visits as opposed to in‐person outpatient appointments. We used national data to evaluate shifts in modes of hepatology outpatient care for patients with cirrhosis during the pandemic. This was a retrospective cohort study among U.S. veterans with cirrhosis. We used linear regression to evaluate absolute and percentage changes from baseline in hepatology in‐person visits and telemedicine visits from January 1, 2020, to August 11, 2020. The proportion of in‐person and telemedicine visits were plotted geographically to demonstrate state‐level shifts in care delivery over time. Patient‐level characteristics in the pre‐COVID and during‐COVID periods were also compared. We identified 5,618 in‐person and 6,210 telemedicine hepatology visits among patients with cirrhosis. In‐person visits significantly declined (−16.0% per week; 95% confidence interval [CI] −20.7, −11.2; P < 0.001), while telemedicine visits significantly increased (61.3% per week; 95% CI 45.1, 77.5; P < 0.001) in the early during‐COVID period. At the U.S. state level, we found that nearly all states experienced a significant shift toward telemedicine over the course of several weeks. Patients over the age of 70 years and Black patients were less likely to receive telemedicine visits in the pre‐COVID period (each P < 0.05), although these differences were eliminated in the during‐COVID periods. Conclusion: Among patients with cirrhosis, hepatology outpatient care delivery has shifted heavily toward telemedicine due to COVID‐19. This occurred across the United States, and changes have been sustained through August 2020. Expanded telemedicine visits among older patients and Black patients may reflect dedicated efforts to increased access to care among these groups.